

Jeremy E Chojnacki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7277371/publications.pdf>

Version: 2024-02-01

19
papers

1,125
citations

687363

13
h-index

940533

16
g-index

21
all docs

21
docs citations

21
times ranked

1835
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Pharmacologic Inhibitor of the NLRP3 Inflammasome Limits Myocardial Injury After Ischemiaâ€“Reperfusion in the Mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 316-322.	1.9	215
2	Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemiaâ€“reperfusion in the mouse. <i>International Journal of Cardiology</i> , 2016, 209, 215-220.	1.7	173
3	NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimerâ€™s Disease. <i>Molecular Neurobiology</i> , 2018, 55, 1977-1987.	4.0	153
4	Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 1-8.	1.9	128
5	Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro- <i>N</i> -[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2194-2201.	3.5	77
6	Bivalent Ligand Containing Curcumin and Cholesterol as a Fluorescence Probe for A β Plaques in Alzheimerâ€™s Disease. <i>ACS Chemical Neuroscience</i> , 2012, 3, 141-146.	3.5	70
7	Discovery of 5-(4-Hydroxyphenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Neuroprotectant for Alzheimerâ€™s Disease by Hybridization of Curcumin and Melatonin. <i>ACS Chemical Neuroscience</i> , 2014, 5, 690-699.	3.5	66
8	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1393-1399.	3.5	51
9	Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 4757.	2.8	47
10	BF ₃ â€“OEt ₂ -promoted concise synthesis of difluoroboron-derivatized curcumins from aldehydes and 2,4-pentanedione. <i>Tetrahedron Letters</i> , 2013, 54, 2070-2073.	1.4	45
11	Dissecting the sequence determinants for dephosphorylation by the catalytic subunits of phosphatases PPI and PP2A. <i>Nature Communications</i> , 2020, 11, 3583.	12.8	38
12	Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimerâ€™s disease. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7324-7331.	3.0	29
13	Bivalent Compound 17MN Exerts Neuroprotection through Interaction at Multiple Sites in a Cellular Model of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1021-1033.	2.6	14
14	Mechanistic Insight of Bivalent Compound 21MO as Potential Neuroprotectant for Alzheimerâ€™s Disease. <i>Molecules</i> , 2016, 21, 412.	3.8	9
15	Structural and mechanistic insights into the interaction of the circadian transcription factor BMAL1 with the KIX domain of the CREB-binding protein. <i>Journal of Biological Chemistry</i> , 2019, 294, 16604-16619.	3.4	9
16	PLDMS: Phosphopeptide Library Dephosphorylation Followed by Mass Spectrometry Analysis to Determine the Specificity of Phosphatases for Dephosphorylation Site Sequences. <i>Methods in Molecular Biology</i> , 2022, , 43-64.	0.9	1
17	P1-400: DEVELOPMENT OF CURCUMIN/MELATONIN HYBRIDS AND THEIR POTENTIAL APPLICATION IN AD. , 2014, 10, P460-P460.		0
18	P4-170: Mechanistic studies of a bivalent compound containing curcumin and a membrane anchorage as a neuroprotectant in mc65 cell model. , 2015, 11, P844-P844.		0

#	ARTICLE	IF	CITATIONS
19	P1-305: Design and evaluation of fluorescent probes to elucidate the mechanism of curcumin/melatonin hybrids for Alzheimer's disease. , 2015, 11, P473-P473.		0